Vertex Signs an Exclusive License Agreement with Merck KGaA for its Two DNA-PK Inhibitor

Shots:

• Merck KGaA to receive upfront, milestones, and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors, M9831 (formerly known as VX-984) and a preclinical candidate for six genetic disease indications to fields of gene-editing
• Vertex will have an option to add indications to the above agreement and Merck will retain rights for its two DNA-PK candidates in all indication (EX- for Vertex) including oncology
• M9831 (formerly known as VX-984) is a DNA-PK inhibitor, evaluated in P-I for solid tumors. In 2017, Merck in-licensed Vertex’s four candidates including its VX-984 DNA-PK Inhibitors for DNA damage and repair

Click here to read full press release/ article | Ref: Merck | Image: Twitter